Boehringer Ingelheim

Clinical Study Synopsis for Public Disclosure

This clinical study synopsis is provided in line with **Boehringer Ingelheim's *Policy on Transparency and Publication of Clinical Study Data***.

The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion.

The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities.

A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country..

Additional information on this study and the drug concerned may be provided upon request based on **Boehringer Ingelheim's Policy on Transparency and Publication of Clinical Study Data**.

Name of Company: Boehringer Ingelheim		**Statement on discontinuation of the study**	Boehringer Ingelheim
BI Proprietary Name: n.a		**EudraCT No.:** 2014-002482-30	
BI Investigational Product: BI 1181181		**Page:** 1	
Report Date: DD Mon YYYY	**Trial No. / Doc. No.:** 1344.2 / c03338942-01	**Dates of Trial:** 11 Nov 2014 – 24 Feb 2015	**Date of Revision:** "Not applicable" ;

Title of Trial:	Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 1181181 given orally q.d. for 10 days in young healthy male and elderly healthy male/female volunteers (randomized, double-blind, placebo controlled within dose groups, Phase I study)
Principal/Coordinating Investigator:	
Trial Sites:	[redacted]
Publications:	n.a.
Clinical Phase:	I

Statement on discontinuation of the study

The trial was terminated prematurely because of a negative benefit risk assessment.